Reported 1 day ago
Jim Cramer recently analyzed Eli Lilly's stock, suggesting that it may not be the next company to reach a $1 trillion market cap due to the current Fed rate cuts. Despite Eli Lilly's impressive products, including significant advancements in diabetes and weight loss drugs, Cramer emphasizes that investing in drug stocks during this economic climate is not advisable. He also points to alternative AI stocks that could offer better investment potential.
Source: YAHOO